RADNOR, Pa., Nov. 05, 2022 (GLOBE NEWSWIRE) — The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against Fulgent Genetics, Inc. (“Fulgent”) in the United States District Court for the Central District of California (NASDAQ:FLGT). The lawsuit alleges Fulgent’s violations of federal securities laws, including omissions and fraudulent misrepresentations regarding the company’s business, operations and prospects. Fulgent investors have suffered significant losses as a result of Fulgent’s materially misleading public statements and omissions.

CLICK HERE SUBMIT YOUR FULFILLMENT LOSSES. YOU CAN ALSO CLICK OR COPY AND PASTE THE FOLLOWING LINK INTO YOUR BROWSER: https://www.ktmc.com/new-cases/fulgent-genetics-inc?utm_source=PR&utm_medium=link&utm_campaign=fulgent&mktm=r

CAN’T WATCH THIS VIDEO? YOU’RE WELCOME CLICK HERE

LIMIT FOR THE PLAINTIFF: NOVEMBER 21, 2022

COURSE PERIOD: MARCH 22, 2019 TO AUGUST 4, 2022

CONTACT AN ATTORNEY TO DISCUSS YOUR RIGHTS:
Jonathan Naji, Esq. at (484) 270-1453 or email at [email protected]

Kessler Topaz is one of the world’s leading advocates for protecting the public from corporate fraud and other wrongdoing. Our securities fraud litigators are consistently recognized individually as leaders in the field, and our firm is feared and respected by both the defense and the Insurance Board. We are proud to have recovered billions of dollars for our clients and the classes of shareholders we represent.

FULGENT’S ALLEGED MISCONDUCT
Fulgent, along with its subsidiaries, provides COVID-19, molecular diagnostics and genetic testing services to physicians and patients in the United States and internationally. As a result, Fulgent must comply with the federal anti-kickback statute, which prohibits knowingly and intentionally paying “compensations” to induce or reward patient referrals or generate business…